Organic Active Ingredients TRIZ Cases

A panel of seven circulating proteins replaces traditional assays to diagnose early-stage chronic kidney disease with higher sensitivity and specificity.

Spherical particles suspend API in liquid medium to maintain stability while improving patient compliance.

Antagonists targeting RIPK1, MLKL, and RIPK3 block the necroptotic signaling cascade to treat liver failure.

Fully human monoclonal antibodies bind Staphylococcus aureus Hemolysin A toxin to neutralize its pore-forming activity.

A pH 10 drinkable formulation resolves astringency and stability trade-offs using maltitol for taste masking.

GPR119 agonists modulate satiety and metabolic functions, addressing dyslipidaemia and hyperglycaemia with reduced side effects.

Benzothiophene compounds act as selective estrogen receptor downregulators to inhibit tumor growth in resistant breast cancer cells.

Periodic pulsed cyclic dosing of IL-2/IL-15Rβγ agonists maintains immune cell activation while preventing cumulative toxicity and vascular leakage syndrome.

Sequential aqueous base neutralization and dehydration remove impurities from SNS-595, achieving pharmaceutical purity without complex downstream processing.

Cyclodextrin inclusion complexes stabilize the benzoate salt of 5MeODMT, resolving formulation difficulties while maintaining therapeutic efficacy.

A pyridoisoquinoline methanol stereoisomer acts as a potent vesicular monoamine transporter 2 inhibitor.

Nanoparticles of tacrolimus increase solubility and bioavailability by bypassing first-pass metabolism via a mucoadhesive buccal film.

Modified physicochemical properties localize FXR agonist activity in the gut, reducing systemic side effects while treating metabolic disorders.

Assaying COL2A and TSG6 gene expression levels differentiates painful from non-painful discs, resolving the lack of objective diagnostic methods for back pain.

10,17-dihydroxyl DHA analogs increase motor neuron viability to address limited functional improvement in amyotrophic lateral sclerosis treatment.

An immunogenic composition combines tissue extract, BCG activator, and formaldehyde mitigator to stimulate targeted immune responses.

Modified pyrrolopyrimidine structures improve liver metabolic stability and pharmacokinetic profiles while maintaining potent autotaxin inhibition.

Combines HDAC6 inhibitor with epothilone to treat paclitaxel-resistant cancers while minimizing adverse effects from broad histone deacetylase inhibition.

Novel bridged diazepane derivatives block TASK channels to stabilize airways and improve respiratory function.

Compounds modulate RNA splicing by interfering with SF3b spliceosome subunit integration to inhibit cancer cell proliferation.

Novel steroid compounds featuring an 11beta-aryl substituent deliver balanced agonistic and antagonistic activity profiles.

A varlitinib malonate salt enables selective crystallization to yield a purer free base form.

Allele-specific DNAzymes cleave mutant EGFR mRNA to overcome tyrosine kinase inhibitor resistance without damaging normal cells.

A hydrophilic copolymer carrying pendant sulphonic groups forms a wound dressing that mimics glycosaminoglycans to regulate moisture.

A YEL002 skin cream formulation merges multiple therapeutic functions into a single topical application.

ALS-iPSC secretome protects neurons from oxidative stress and protein aggregation, delaying disease onset in ALS models.

A buccal micro-effervescent tablet generates mild effervescence upon contact with saliva for direct oral nutrient delivery.

Specific compounds inhibit CRM1 activity to restore tumor suppressor function in cancer cells.

Pyrazolyl-pyrimidine derivatives selectively inhibit kinases like PIM1 and JAK2, reducing peripheral neuropathy caused by conventional mitotic inhibitors.

Dry granulation avoids wet processing polymorphic conversion, maintaining etoricoxib solubility and stability.

Composite probiotics with Hericium erinaceus and prebiotics improve intestinal health by increasing beneficial microorganism concentration.

Removing fine particle fractions from uncoated ibuprofen eliminates bitter taste without complex coatings, reducing manufacturing complexity.

IU1-series compounds block USP14 deubiquitinase activity, preventing substrate rescue and significantly enhancing PROTAC anticancer efficacy.

Lentivirus-infected mesenchymal stem cells produce circCDK13-enriched sEVs that overcome poor cell membrane penetration of large circular RNA molecules.

Stable multimerized Fc fusion proteins overcome IVIG limitations by reducing protein load and infectious risk while maintaining high therapeutic efficacy.

Refrigerating diluted concentrates at 2 to 15°C resolves the trade-off between processing speed and substance loss, maintaining high plasmalogen yields.

Antisense oligonucleotides reduce STAT3 protein levels via hybridization, resolving ineffective inhibition of hyperproliferative diseases.

7-deazapurine nucleosides overcome inadequate anti-cancer therapies by inhibiting tumor growth and inducing apoptosis.

Novel alpha-hemolysin inhibitors block bacterial virulence factors to prevent lung tissue damage and pathogenesis.

Combining antifibrotic peptides with agents like nintedanib targets multiple pathways to improve efficacy while reducing adverse effects.

Carboxycellulose prevents fiber aggregation during concentration, enabling easy re-dispersion and high dry matter content.

Antisense polynucleotide agents bind to angiotensinogen mRNA to inhibit gene expression, reducing hypertension without cumulative side effects.

Substituted pyridazinone compounds inhibit fast-fiber skeletal muscle myosin II, reducing muscle breakdown and inflammation in Duchenne Muscular Dystrophy.

Formula I compounds bind eIF4E to disrupt cap-dependent translation, addressing the lack of effective inhibitors for dysregulated protein function.

Albumin binding peptide-drug conjugates extend plasma half-life and tumor accumulation while reducing systemic toxicities.

Optimized molecular structures enhance inhibitor stability while reducing off-target effects.

Determining CD90 expression levels selects glioblastoma patients for dasatinib therapy, overcoming resistance to standard chemotherapy and radiotherapy.

Formula I compounds inhibit gamma secretase activity, reducing amyloid-beta levels to slow cognitive decline in Alzheimer's patients.